IL2RA and hepatocellular carcinoma: The univariable analysis showed that the chances of surviving after transplant were higher for recipients of younger grafts (p = 0.0009), younger patients (p < 0.0001), female patients (p = 0.005), those with non-HCV liver disease as the reason for transplantation (p < 0.0001), no presence of HCC at transplant (p = 0.001), a lower laboratory MELD score (p = 0.002), the use of anti-IL2R as an induction agent (p < 0.0001), TAC as the primary immunosuppressant (p < 0.0001), and no occurrence of DM one year after transplant (p = 0.01) (Table 4).